-
New domestic anti-cancer drugs embark on a virtuous circle, and many pharmaceutical companies recently announced new breakthroughs
Time of Update: 2022-01-10
For example, Zhejiang Medicine issued an announcement recently that the company's subsidiary Xinma Biology's new anti-cancer drug, a recombinant humanized anti-CD70 monoclonal antibody-AS269 conjugate for injection (code: ARX305), has been accepted for registration of clinical trials .
Increasing the innovative research and development of domestic anti-tumor drugs to provide more cancer patients with new drug treatment options.
-
Pfizer's 10 years of experience and lessons in increasing the clinical success rate from 2% to 21%
Time of Update: 2022-01-10
Recently, a recent report on the success rate of drug clinical development showed that the average success rate of drug development projects from phase 1 clinical trials to the approval of the US FDA for marketing in the past ten years was 7.
-
KPTI and Menarini Sign Exclusive License Agreement for Drug Commercialization
Time of Update: 2022-01-10
NEXPOVIO has obtained a conditional marketing authorization from the European Commission to treat adult patients with related multiple myeloma combined with dexamethasone, that is, they have received at least four previous therapies, and their disease uses at least two proteasome inhibitors and two immunizations The modulator and an anti-CD38 monoclonal antibody are incurable, and patients who showed progression of the disease in the last treatment .
-
Inventory of innovative drugs approved by NMPA in 2021
Time of Update: 2022-01-10
On December 21, 2021, the National Medical Products Administration approved the import registration application of Orfatumumab Injection (English name: Ofatumumab Injection) for the treatment of rare diseases through the priority review and approval procedure .
-
"Innovative Drug One Brother" is amazing!
Time of Update: 2022-01-10
According to data from Meinenet, in the past week, Hengrui Medicine has 7 new drugs (6 of which are Class 1 new drugs) for clinical application .
-
CanSino Announces Global Multi-center Phase 3 Clinical Data of Adenovirus Vector Covid-19 Vaccine
Time of Update: 2022-01-10
On December 24th, CanSino Bio announced that it has published a global multi-center phase 3 clinical trial of the recombinant new coronavirus vaccine (type 5 adenovirus vector) in the international authoritative medical journal "The Lancet" recently.
com/s/0C8zVm2yrPAsQA-QPl3gSw[1] Heavyweight | Global multi-center phase 3 clinical data released for the first domestic adenovirus vector new crown vaccine.
-
Novartis acquires Gyroscope, an ophthalmic gene therapy company, for $1.5 billion
Time of Update: 2022-01-10
The core product GT005 of Gyroscope Therapeutics is a one-time gene therapy based on AAV2 vector, which is intended to be developed to treat age-related macular degeneration (AMD) secondary geographic atrophy .
-
Official announcement!
Time of Update: 2022-01-10
” The notice pointed out that in accordance with the relevant requirements of the "Henan, Jin, Mongolia, Jiangxi, Guangdong, Guiyu, Guiyu, Yunnan, Shaanxi, Qingning and Ningxin Corps 14 provinces (autonomous regions, municipalities, corps) drug joint procurement documents" (number: YPLH-YD2021-1) and other relevant requirements , Now the 14 provinces (autonomous regions, municipalities, and corps) of Henan, Jin, Mongolia, Jiangxi, Jiangxi, Guangdong, Gui Yu, Yunnan, Shaanxi, Qinghai and Ningxia New Corps will be publicized.
-
Innovative drug transactions among domestic pharmaceutical companies are very hot, and both the number and amount have reached new highs
Time of Update: 2022-01-10
In recent years, as the country vigorously promotes the development of the pharmaceutical innovation industry, the number of license-in/out projects between pharmaceutical companies has increased significantly, and the transaction amount has also begun to continue to grow .
-
Review and Prospect of Top 10 New Drug Frontier Hot Spots
Time of Update: 2022-01-09
【review】 [Prospect] Whether the many domestically produced PD-(L)1 accepted by the FDA can be successfully approved will become the cornerstone for testing the quality of its products and clinical trial data, and it will also open up a fan for the current domestic research on biological drugs to enter the international market Window .
-
In or Out?
Time of Update: 2022-01-09
License-in: To make up for the shortcomings of the enterprise and realize "overtaking in corners"License-in: To make up for the shortcomings of the enterprise and realize "overtaking in corners" Domestic pharmaceutical companies have introduced early projects from overseas companies to increase the probability of innovative drug research and development, and quickly enrich the company's product pipeline.
-
Nine potential blockbuster treatments expected to be approved in 2022
Time of Update: 2022-01-09
In the “Lancet” magazine last October, Eli Lilly published the detailed phase 3 clinical results of the innovative treatment-in adult patients with type 2 diabetes with increased cardiovascular risk, compared with insulin glargine, three All doses of tirzepatide showed better curative effect, and reduced the level of glycated hemoglobin (A1C) (maximum dose 2.
-
Looking at how the pharmaceutical industry in the post-epidemic era will innovate and transform from the guiding principles of anti-tumor drugs
Time of Update: 2022-01-09
Strengthen mechanism research The US FDA accelerated the approval of Amgen’s KRASG12C inhibitor Lumakras on May 28 for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) patients with KRASG12C mutations who have received at least one systemic treatment in the past .
-
2021 inventory: the first category of chemical medicines IND exceeds 243, Hengrui and Zhengda Tianqing lead the way!
Time of Update: 2022-01-09
Assembling other surrounding cities in the Yangtze River Delta region, in 2021, the number of first IND applications for chemical category 1 innovative drugs will reach 141, accounting for 58% of the national total.
-
The "first" new drug approved globally in 2021
Time of Update: 2022-01-09
Rybrevant (Amivantamab-vmjw), an EGFR-MET bispecific antibody with immune cell targeting activity, was approved by the FDA in May for the treatment of disease progression after failure of platinum-containing chemotherapy and positive EGFR gene exon 20 insertion mutation ( Adult patients with metastatic non-small cell lung cancer (mNSCLC) with EGFRex20ins+ have become the world's first targeted therapy approved for the treatment of EGFRex20ins+ NSCLC .
-
Looking at the EU's drug authorization system in the context of the global epidemic
Time of Update: 2022-01-09
Reg. 726/2004/EC regulations stipulate that “in order to meet the reasonable expectations of specific patients and take into account the rapid development of science and treatment methods, an accelerated review procedure should be established, and drugs with significant therapeutic benefits should be retained and obtained according to the annual review conditions.
-
Express delivery potential amount exceeds 1.2 billion U.S. dollars, Sanofi acquires tumor immunotherapy development company
Time of Update: 2022-01-09
The protease release stealth Pro-XTEN (Protease-Releasable Masking Technology) technology platform developed by Amunix utilizes the inherent high protease activity in the tumor microenvironment to preferentially activate drugs, thereby reducing toxicity without affecting normal tissues .
-
Innovation is on the way!
Time of Update: 2022-01-09
2021, which is about to end, will be another year when the achievements of innovative drugs will shine . According to incomplete statistics, China’s National Food and Drug Administration (NMPA) appr
-
AGCO Baifa and Commave signed an exclusive license agreement for the new drug AZSTARYS® for the treatment of attention deficit hyperactivity disorder in Greater China
Time of Update: 2022-01-09
("AGCO Biopharma"), a biomedical company focusing on the development of innovative drugs, announced on December 28, 2021 that its subsidiaries Ark Biopharmaceutical Limited and Gurnet Point Capital (GPC )'S Commave Therapeutics, SA (Commave) signed an exclusive license agreement to trade a first innovative drug AZSTARYS® for the treatment of ADHD .
-
High-collared Shigekura, winning the prize and getting soft, what is the potential of this biopharmaceutical company?
Time of Update: 2022-01-09
The product is currently undergoing phase 2 clinical trials for the treatment of solid tumors in China and the United States, and its clinical progress ranks among the top three in the global competition .
